[SCHEDULE 13G/A] 2seventy bio, Inc. SEC Filing

Rhea-AI Filing Summary

2seventy bio, Inc. Schedule 13G/A shows The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly report beneficial ownership of 308 shares of the issuer's common stock. The filers state no sole voting or dispositive power and report shared voting power of 133 shares and shared dispositive power of 308 shares. The reported amount represents 0.0% of the class and is described as ownership of 5% or less. The filers certify the securities are held in the ordinary course of business and not for the purpose of changing control. The filing includes a joint filing agreement and identifies GS Group as a parent holding company with Goldman Sachs as a subsidiary broker-dealer and investment adviser.

Positive

• Joint filing agreement included, clarifying reporting responsibilities between GS Group and Goldman Sachs & Co. LLC
• Ownership is 5% or less, reported as 308 shares (0.0% of class), indicating a de minimis stake
• Filers certify holdings are in the ordinary course of business and not intended to influence control

Negative

• None.

Insights

Financial Analyst

TL;DR: Reported holdings are de minimis—308 shares (0.0%), indicating no material economic or control stake.

The Schedule 13G/A discloses a small, jointly reported position of 308 shares in 2seventy bio. With 0 sole voting/dispositive power and only 133 shared votes, this holding is immaterial to ownership concentration and unlikely to affect capitalization or governance. The filing's certification that the shares are held in the ordinary course and the inclusion of a joint filing agreement confirm routine custody/trading or advisory activity rather than an activist intent. Impact on investors is neutral.

Corporate Governance Expert

TL;DR: Legal formality of joint Schedule 13G/A; ownership and voting influence are negligible.

The report identifies GS Group and its subsidiary as joint filers and classifies the positions under standard reporting types. The combination of no sole power, shared voting power of 133, and an overall stake of 308 shares (0.0%) indicates no practical governance influence. The explicit certification that holdings are not intended to change or influence control reduces regulatory and activist signaling. This disclosure is routine and non-impactful for board-level or strategic considerations.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

2SEVENTY BIO, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

901384107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 901384107

1

Names of Reporting Persons

THE GOLDMAN SACHS GROUP, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 133.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 308.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

308.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 901384107

1

Names of Reporting Persons

GOLDMAN SACHS & CO. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 133.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 308.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

308.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

BD, OO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: 2SEVENTY BIO, INC.
(b)	Address of issuer's principal executive offices: 60 BINNEY STREET, CAMBRIDGE, X1, 02142
Item 2.
(a)	Name of person filing: THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
(b)	Address or principal business office or, if none, residence: The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
(c)	Citizenship: THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 901384107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: See the response(s)to Item 11 on the attached cover page(s).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit (99.2)
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

THE GOLDMAN SACHS GROUP, INC.

Signature:	Name: Abhilasha Bareja
Name/Title:	Attorney-in-fact
Date:	07/17/2025

GOLDMAN SACHS & CO. LLC

Signature:	Name: Abhilasha Bareja
Name/Title:	Attorney-in-fact
Date:	07/17/2025

Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of 2SEVENTY BIO, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 07/17/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ Abhilasha Bareja ---------------------------------------- Name: Abhilasha Bareja Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ Abhilasha Bareja ---------------------------------------- Name: Abhilasha Bareja Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group.

FAQ

How many shares does Goldman Sachs report beneficially owning in TSVT?

The filers report 308 shares beneficially owned.

What voting and dispositive powers are reported for Goldman Sachs in TSVT?

The filing shows 0 sole voting power, 133 shared voting power, 0 sole dispositive power, and 308 shared dispositive power.

What percentage of 2seventy bio (TSVT) does the reported position represent?

The reported position represents 0.0% of the class, and is described as ownership of 5% or less.

Did the filers indicate an intent to influence control of TSVT?

No. The filers certify the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.

Who are the reporting persons on this Schedule 13G/A for TSVT?

The reporting persons are The Goldman Sachs Group, Inc. (parent holding company) and Goldman Sachs & Co. LLC (subsidiary broker-dealer and investment adviser).